These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
477 related articles for article (PubMed ID: 24722067)
1. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Cao B; Qi Y; Zhang G; Xu D; Zhan Y; Alvarez X; Guo Z; Fu X; Plymate SR; Sartor O; Zhang H; Dong Y Oncotarget; 2014 Mar; 5(6):1646-56. PubMed ID: 24722067 [TBL] [Abstract][Full Text] [Related]
2. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322 [TBL] [Abstract][Full Text] [Related]
3. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model. Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672 [TBL] [Abstract][Full Text] [Related]
4. Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance. Zhan Y; Zhang G; Wang X; Qi Y; Bai S; Li D; Ma T; Sartor O; Flemington EK; Zhang H; Lee P; Dong Y Mol Cancer Res; 2017 Jan; 15(1):59-68. PubMed ID: 27671337 [TBL] [Abstract][Full Text] [Related]
5. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Zhu Y; Dalrymple SL; Coleman I; Zheng SL; Xu J; Hooper JE; Antonarakis ES; De Marzo AM; Meeker AK; Nelson PS; Isaacs WB; Denmeade SR; Luo J; Brennen WN; Isaacs JT Oncogene; 2020 Nov; 39(45):6935-6949. PubMed ID: 32989253 [TBL] [Abstract][Full Text] [Related]
6. TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer. Yoshida S; Kajiwara D; Seki M; Tayama M; Tanaka Y; Mizutani H; Fujita R; Yamamura K; Okajima S; Asai M; Minamiguchi K Mol Oncol; 2024 Aug; 18(8):1980-2000. PubMed ID: 38600681 [TBL] [Abstract][Full Text] [Related]
7. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814 [TBL] [Abstract][Full Text] [Related]
8. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436 [TBL] [Abstract][Full Text] [Related]
9. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer. Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685 [TBL] [Abstract][Full Text] [Related]
10. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth. Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993 [TBL] [Abstract][Full Text] [Related]
11. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer. Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482 [TBL] [Abstract][Full Text] [Related]
12. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. Kregel S; Wang C; Han X; Xiao L; Fernandez-Salas E; Bawa P; McCollum BL; Wilder-Romans K; Apel IJ; Cao X; Speers C; Wang S; Chinnaiyan AM Neoplasia; 2020 Feb; 22(2):111-119. PubMed ID: 31931431 [TBL] [Abstract][Full Text] [Related]
13. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer. Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514 [TBL] [Abstract][Full Text] [Related]
14. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960 [TBL] [Abstract][Full Text] [Related]
15. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer. Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515 [No Abstract] [Full Text] [Related]
16. Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance. Wu H; You L; Li Y; Zhao Z; Shi G; Chen Z; Wang Z; Li X; Du S; Ye W; Gao X; Duan J; Cheng Y; Tao W; Bian J; Zhou JR; Zhu Q; Yang Y Cancer Res; 2020 Jul; 80(13):2927-2939. PubMed ID: 32341037 [TBL] [Abstract][Full Text] [Related]
17. FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer. Jones D; Wade M; Nakjang S; Chaytor L; Grey J; Robson CN; Gaughan L Oncotarget; 2015 Oct; 6(30):29782-94. PubMed ID: 26336819 [TBL] [Abstract][Full Text] [Related]
18. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Liu C; Armstrong C; Zhu Y; Lou W; Gao AC Oncotarget; 2016 May; 7(22):32210-20. PubMed ID: 27049719 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer. Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587 [TBL] [Abstract][Full Text] [Related]
20. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Li Y; Chan SC; Brand LJ; Hwang TH; Silverstein KA; Dehm SM Cancer Res; 2013 Jan; 73(2):483-9. PubMed ID: 23117885 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]